English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, February 13, 2019
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
エーザイ、人事異動ならびに組織改編(2019年2月12日付)を発表
Monday, February 4, 2019
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
エーザイ、レンボレキサントのピボタル臨床第III相試験における有効性・安全性データについて米国睡眠学会のAdvances in Sleep and Circadian Scienceで発表
Wednesday, January 30, 2019
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
エーザイ、抗てんかん剤「フィコンパ(R)」が日本において部分てんかんの単剤療法および小児適応、並びに新規剤形の追加を申請
Wednesday, January 23, 2019
エーザイ、「世界で最も持続可能な100社」に4回目の選定
Tuesday, January 22, 2019
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Friday, January 18, 2019
Eisai's Notification Regarding Results of Voluntary Retirement Program
エーザイ、希望退職者の募集の結果に関するお知らせ

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575